+22.5%
KORU vs MRNA
+945.0%
-922.5%
-83.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.3% | +13.1% | -18.4% | -6.9% |
| 7D | -24.3% | +20.6% | -45.0% | -26.2% |
| 30D | -54.2% | +27.1% | -81.4% | -55.5% |
| 3M | -45.4% | +353.4% | -398.8% | -60.3% |
| 6M | -66.5% | +446.3% | -512.7% | -79.0% |
| YTD | +14.9% | +776.2% | -761.3% | -34.4% |
| 1Y | +22.5% | +987.9% | -965.4% | -38.1% |
| All | +22.5% | +945.0% | -922.5% | -38.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling